Plain-English translation of NCT04263922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a Chinese herbal medicine, can help treat a common type of chronic kidney disease. About 466 people will take either the medication combined with a placebo, or a standard kidney medicine (valsartan) combined with a placebo, for 48 weeks. Researchers want to see if this treatment can slow kidney damage and reduce protein loss in the urine.
Chronic kidney disease affects millions of people worldwide, and many cases are caused by inflammation in the filtering units of the kidney. Currently, there are limited treatment options available for this condition, so researchers are testing whether this medication might offer another way to help protect kidney function.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic at the start of the study and then every 8 weeks for 48 weeks (about 12 months total). At each visit, you'll take your assigned medication — either the herbal medicine with a placebo pill, or the standard kidney medicine with a placebo granule — so neither you nor the doctors will know which treatment you're receiving. The study team will monitor your kidney function, blood pressure, and urine protein through regular blood and urine tests to see how well the treatment works.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China